PHIO Phio Pharmaceuticals Corp.

NEUTRAL Impact: 5/10 8-K
Horizon weeks Filed Apr 8, 2026 Processed 2mo ago SEC 0001437749-26-011761
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Latest settled — T+20d ⚠ clustered
PHIO ▼ -8.00% at T+20d
NEUTRAL call ✗ call lost -8.00% · α vs SPY -15.57% · entry $1.25 → $1.15
Next anchor: T+60d in 20d
Currently $1.07 · -14.40% from $1.25 entry
Entry anchored
Apr 8, 03:59 PM ET
via Databento tick
T+1d
-3.20%
call -3.20% · α -3.14%
$1.21
settled 2mo ago
T+5d
+1.60%
call +1.60% · α -1.59%
$1.27
settled 8w ago
T+20d
-8.00%
call -8.00% · α -15.57%
$1.15
settled 5w ago
T+60d
call — · α —
in 20d

Price Chart

Loading chart...

Executive Summary

Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock. This capital raise follows a recent shelf registration and is intended to fund development of PH-762 and general working capital. The offering introduces potential near-term dilution.

Key Financial Metrics

Deal Value
$6.4M

Actionable Insight

Monitor for actual sales under this ATM program, as the $6.36 million represents a ceiling rather than a guaranteed amount. The capital will support PH-762 development but introduces dilution risk. Check future 10-Q filings for disclosure of shares sold and net proceeds received.

Key Facts

  • Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock
  • The offering is being conducted pursuant to a shelf registration statement declared effective on July 1, 2024
  • Proceeds will be used to advance PH-762 into a Phase 2b/3 trial and for general working capital
  • H.C. Wainwright will receive a 3.0% commission on gross proceeds from sales
  • The company has no obligation to sell any shares and may suspend or terminate the offering at any time

Financial Impact

Up to $6.36 million in potential proceeds, with 3.0% commission paid to the placement agent

dilutioncashworking capital

Risk Factors

  • Dilution to existing shareholders if the full $6.36 million is raised
  • Potential downward pressure on stock price from incremental share issuance
  • No assurance that any shares will be sold under the agreement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-011761
Exhibit: ex_942764.htm0001437749-26-011761
Document: phio20260402_8k.htm0001437749-26-011761
Document: 0001437749-26-011761-index-headers.html0001437749-26-011761
Document: 0001437749-26-011761-index.html0001437749-26-011761
Document: 0001437749-26-011761.txt0001437749-26-011761
3 reports for PHIO
Performance horizon
Filters
Rows
Reports for PHIO — sortable, filterable
Type Now
Apr 8, 2026
9w ago
8-K
NEUTRAL ★ 5/10
$1.25 $1.15▼ −8.00%▼ −15.57%$1.07 (−14.40%)
Apr 8, 2026
9w ago
424B5
NEUTRAL ★ 5/10
$1.25 $1.15▼ −8.00%▼ −15.57%$1.07 (−14.40%)
Mar 5, 2026
14w ago
8-K
MIXED ★ 6/10
$1.16 $1.26▲ +8.62%▲ +10.67%$1.07 (−7.76%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (49h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access